Patient-derived xenograft tumor models revealed that inducing IFN-driven T cell responses with avadomide could convert non-inflamed CLL tumors into CD8+ T cell-inflamed TMEs that responded to anti-PD-L1/PD-1-based combination therapy. Here, PDCD1 is linked to neoplasm.